108 related articles for article (PubMed ID: 20869877)
1. Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90.
Nardelli A; Castaldi E; Ortosecco G; Speranza A; Storto G; Pace L; Salvatore M
Appl Radiat Isot; 2011 Jan; 69(1):52-5. PubMed ID: 20869877
[TBL] [Abstract][Full Text] [Related]
2. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities.
Breeman WA; De Jong M; Visser TJ; Erion JL; Krenning EP
Eur J Nucl Med Mol Imaging; 2003 Jun; 30(6):917-20. PubMed ID: 12677301
[TBL] [Abstract][Full Text] [Related]
3. Radiolabelling, quality control and radiochemical purity assessment of the Octreotide analogue 68Ga DOTA NOC.
Di Pierro D; Rizzello A; Cicoria G; Lodi F; Marengo M; Pancaldi D; Trespidi S; Boschi S
Appl Radiat Isot; 2008 Aug; 66(8):1091-6. PubMed ID: 18226535
[TBL] [Abstract][Full Text] [Related]
4. Radiolabelling DOTA-peptides with 68Ga.
Breeman WA; de Jong M; de Blois E; Bernard BF; Konijnenberg M; Krenning EP
Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):478-85. PubMed ID: 15655678
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution of two octreotate analogs radiolabeled with indium and yttrium in rats.
Laznickova A; Laznicek M; Trejtnar F; Maecke HR; Eisenwiener KP; Reubi JC
Anticancer Res; 2010 Jun; 30(6):2177-84. PubMed ID: 20651367
[TBL] [Abstract][Full Text] [Related]
6. Radiolabelling of glucose-Tyr3-octreotate with 125I and analysis of its metabolism in rats: comparison with radiolabelled DOTA-Tyr3-octreotate.
Petrik M; Laznickova A; Laznicek M; Zalutsky MR
Anticancer Res; 2007; 27(6B):3941-6. PubMed ID: 18225554
[TBL] [Abstract][Full Text] [Related]
7. Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.
de Jong M; Breeman WA; Bernard BF; Bakker WH; Visser TJ; Kooij PP; van Gameren A; Krenning EP
J Nucl Med; 2001 Dec; 42(12):1841-6. PubMed ID: 11752083
[TBL] [Abstract][Full Text] [Related]
8. Regressive DOTA labelling performance with indium-111 and yttrium-90 over a week of use.
Hainsworth JE; Mather SJ
Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1348. PubMed ID: 16142470
[No Abstract] [Full Text] [Related]
9. Preclinical and clinical studies of peptide receptor radionuclide therapy.
Pool SE; Krenning EP; Koning GA; van Eijck CH; Teunissen JJ; Kam B; Valkema R; Kwekkeboom DJ; de Jong M
Semin Nucl Med; 2010 May; 40(3):209-18. PubMed ID: 20350630
[TBL] [Abstract][Full Text] [Related]
10. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
[TBL] [Abstract][Full Text] [Related]
11. Development and Evaluation of User-Friendly Single Vial DOTA-Peptide Kit Formulations, Specifically Designed for Radiolabelling with
Prince D; Rossouw D; Davids C; Rubow S
Mol Imaging Biol; 2017 Dec; 19(6):817-824. PubMed ID: 28341976
[TBL] [Abstract][Full Text] [Related]
12. Single vial kit formulation of DOTATATE for preparation of (177) Lu-labeled therapeutic radiopharmaceutical at hospital radiopharmacy.
Mukherjee A; Lohar S; Dash A; Sarma HD; Samuel G; Korde A
J Labelled Comp Radiopharm; 2015 Apr; 58(4):166-72. PubMed ID: 25765604
[TBL] [Abstract][Full Text] [Related]
13. Complexation and biodistribution study of 111In and 90Y complexes of bifunctional phosphinic acid analogs of H4dota.
Försterová M; Petrík M; Láznicková A; Láznícek M; Hermann P; Lukes I; Melichar F
Appl Radiat Isot; 2009 Jan; 67(1):21-9. PubMed ID: 18951809
[TBL] [Abstract][Full Text] [Related]
14. On the preparation of a therapeutic dose of 177Lu-labeled DOTA-TATE using indigenously produced 177Lu in medium flux reactor.
Das T; Chakraborty S; Banerjee S; Venkatesh M
Appl Radiat Isot; 2007 Mar; 65(3):301-8. PubMed ID: 17110119
[TBL] [Abstract][Full Text] [Related]
15. Optimization of reaction conditions for the radiolabeling of DOTA and DOTA-peptide with (44m/44)Sc and experimental evidence of the feasibility of an in vivo PET generator.
Huclier-Markai S; Kerdjoudj R; Alliot C; Bonraisin AC; Michel N; Haddad F; Barbet J
Nucl Med Biol; 2014 May; 41 Suppl():e36-43. PubMed ID: 24361353
[TBL] [Abstract][Full Text] [Related]
16. Influence of cations on the complexation yield of DOTATATE with yttrium and lutetium: a perspective study for enhancing the 90Y and 177Lu labeling conditions.
Asti M; Tegoni M; Farioli D; Iori M; Guidotti C; Cutler CS; Mayer P; Versari A; Salvo D
Nucl Med Biol; 2012 May; 39(4):509-17. PubMed ID: 22172388
[TBL] [Abstract][Full Text] [Related]
17. NMR studies reveal structural differences between the gallium and yttrium complexes of DOTA-D-Phe1-Tyr3-octreotide.
Deshmukh MV; Voll G; Kühlewein A; Mäcke H; Schmitt J; Kessler H; Gemmecker G
J Med Chem; 2005 Mar; 48(5):1506-14. PubMed ID: 15743193
[TBL] [Abstract][Full Text] [Related]
18. Direct synthesis of [DOTA-DPhe1]-octreotide and [DOTA-DPhe1,Tyr3]-octreotide (SMT487): two conjugates for systemic delivery of radiotherapeutical nuclides to somatostatin receptor positive tumors in man.
Albert R; Smith-Jones P; Stolz B; Simeon C; Knecht H; Bruns C; Pless J
Bioorg Med Chem Lett; 1998 May; 8(10):1207-10. PubMed ID: 9871736
[TBL] [Abstract][Full Text] [Related]
19. N-terminal sugar conjugation and C-terminal Thr-for-Thr(ol) exchange in radioiodinated Tyr3-octreotide: effect on cellular ligand trafficking in vitro and tumor accumulation in vivo.
Schottelius M; Reubi JC; Eltschinger V; Schwaiger M; Wester HJ
J Med Chem; 2005 Apr; 48(8):2778-89. PubMed ID: 15828816
[TBL] [Abstract][Full Text] [Related]
20. Radiolabeling of DOTATOC with the long-lived positron emitter 44Sc.
Pruszyński M; Majkowska-Pilip A; Loktionova NS; Eppard E; Roesch F
Appl Radiat Isot; 2012 Jun; 70(6):974-9. PubMed ID: 22464928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
